Rheumatoid Arthritis
Holding abatacept, TNFi unnecessary for receiving COVID-19 booster
SAN DIEGO — COVID-19 vaccine boosters led to a significantly increased antibody response in patients using abatacept or TNF inhibitors regardless of whether they held medication, according to data presented at ACR Convergence 2023.
Three-quarters of patients in RA remission flare within 3 years of TNF inhibitor taper
SAN DIEGO — Approximately 75% of patients in rheumatoid arthritis remission who taper TNF inhibitors to withdrawal experience a flare within 3 years, according to data presented at ACR Convergence 2023.
‘Tough to say’: Complications, guarded optimism surround Medicare price negotiations
Following HHS’ blockbuster announcement of the first 10 drugs that would be subject to Medicare price negotiations, patients and providers alike have been looking forward to meaningful reductions in their costly treatments.
Therapy choice in rheumatoid arthritis does not impact serious infection risk
Among patients with rheumatoid arthritis, the chosen course of therapy does not have an impact on the risk for developing a serious infection, according to data published in Rheumatology.
Work disability due to inflammatory arthritis greater among lower-paid, manual jobs
People who work lower-paid, manual-labor jobs are more likely to discontinue employment in the first 5 years after an early inflammatory arthritis diagnosis, vs. those who work in managerial or professional capacities, according to data.
VIDEO: Investigating phenotypes of rheumatoid arthritis-associated interstitial lung disease
SAN DIEGO — In this Healio video, Jeffrey A. Sparks, MD, MMSc, highlighted studies from members of his group at Brigham and Women’s Hospital that were presented at ACR Convergence 2023.
Immunosuppressed patients may accrue skin cancer at higher rates than healthy patients
Patients with certain autoimmune and inflammatory conditions may develop cutaneous squamous cell carcinoma at higher rates than immunocompetent patients, according to a study.
VIDEO: TNF inhibitors safe for RA-ILD, but ‘unlikely they have much efficacy’
SAN DIEGO — In this video, Jeffrey A. Sparks, MD, MMSc, spoke with Healio about the safety of TNF inhibitors compared with alternative targeted therapies for patients with rheumatoid arthritis-associated interstitial lung disease.
Adalimumab biosimilar SB5 shows high persistence, no new safety signals through 48 weeks
Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.
VIDEO: Administering medication through the lymphatic system for rheumatoid arthritis
SAN DIEGO — In this Healio video, Jeffrey A. Sparks, MD, MMSc, discusses results from a proof-of-concept study that assessed the efficacy of administering medication for rheumatoid arthritis into the peripheral lymphatic systems.